CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
IMC-11F8 +2 morebiological
Likely dose
IMC-11F8 600 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01088464
NCT01088464Phase 1Completed
CompareCT.gov

A Phase 1 Study of IMC-11F8 in Patients With Advanced Solid Tumors

Eli Lilly and Company·interventional·Posted Mar 17, 2010·Updated Feb 3, 2017

In Brief

A Phase 1 clinical trial evaluating IMC-11F8 for Neoplasms. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This study is to establish the safety and pharmacokinetic (PK) profile of IMC-11F8, administered either: (1) in a 3-week cycle; or (2) in a 2-week cycle to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesJapan
CollaboratorsParexel

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 17, 2010
Enrollment StartJan 1, 2010
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.3 years ago

Interventions

IMC-11F8biological

600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks

IMC-11F8biological

800 mg intravenously, every 2 weeks

IMC-11F8biological

800 mg intravenously, Days 1 and 8 every 3 weeks